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The establishment of the diagnosis of cutaneous malignant melanoma (CMM) always calls for histopathological conﬁrmation.
Further to the recognition of the CMM aspects, immunohistochemistry is helpful, in particular, in determining the size of the
replicative compartment and the activity in each of the cell cycle phases (G1,S ,G 2, M). The involvement of cancer stem cells and
transient ampliﬁer cells in CMM genesis is beyond doubt. The proliferation activity is indicative of the neoplastic progression and
is often related to the clinical growth rate of the neoplasm. It allows to distinguish high-risk CMM commonly showing a high
growth rate, from those CMMs of lower malignancy associated with a more limited growth rate. The recruitment and progression
of CMM cells in the cell cycle of proliferation depend on mitogen-activated protein kinase (MAPK) pathway and result from a loss
of control normally involving a series of key regulatory cyclins. In addition, the apoptotic pathways potentially counteracting any
excess in proliferative activity are out of the dependency of speciﬁc regulatory molecular mechanisms. Key molecular components
involved in the deregulation of the growth fraction, the cell cycle phases of proliferation, and apoptosis are presently described in
CMM.
1.Introduction
For years, the incidence of human cutaneous malignant
melanoma (CMM) is steadily on the rise [1]. CMM repre-
sents the leading cause of skin cancer death in the Caucasian
populations from Westernized societies [2, 3]. Survival is
dramatically decreased when distant metastases develop.
Mortality rates vary by country, gender, and ethnic origin.
For decades,physicianssearchedforpredictive indicators
of the CMM metastatic risk. The regular classiﬁcation and
staging of sporadic CMM rely on the combination of gross
clinical and microscopic aspects [4, 5]. However, in some
instances, the distinction of CMM from other atypical
melanocytic neoplasms and the CMM staging prove to
be diﬃcult or uncertain [6]. The reﬁnement of diagnostic
assessments beneﬁts from complementary immunohisto-
chemical investigations [7–12]. Recent progress in the ﬁeld
of molecular biology brings further information resolving
a series of translational quandaries [13–16]. In particular,
it appears that transient ampliﬁer neoplastic melanocytes,
as well as melanocytic stem cells, participate in the CMM
initiation and progression [15, 17–24].
Basically, most CMMs begin with the so-called radial
growth phase corresponding to a slow-growing in situ and
microinvasive phase. This condition is characterized by
a high cure rate. Despite a trend toward earlier clinical
recognition of CMM, by the time of diagnosis, most of the
CMMs have already progressed to the next vertical growth
phase typical for tumorigenic CMM and characterized by a
faster growth rate [24]. In these neoplasms, cure becomes
uncertain, and the prognosis depends on certain attributes
of both the neoplasm and the host (stroma, immunity, etc.).
In general, the CMM clinical progression appears in part
correlated with the enlargement of its germinative compart-
ment [23, 24]. The proportion of CMM cells engaged in the
cellcycleofproliferationisincreasingaswell.However,some
cases of smouldering CMM, CMM dormancy, and CMM
regression exhibit peculiar aspects of tumor progression and
cell proliferation [25–27].2 ISRN Dermatology
2. Smouldering CMM
A variety of interrelations between CMM cells and the host
are under the control of a vast array of factors. These interac-
tions are not static, but result from a ﬂuctuating imbalance
between the neoplasm and the host, both being engaged
in a process of natural selection. The variable combination
over time of diﬀerent cell processes involving CMM and
its microenvironment possibly leads to a condition coined
smouldering CMM [27].
The smouldering CMM concept was raised following a
seminal study on CMM performed over more than 20 years
[25]. The observational study scrutinized how the CMM
metastases possibly varied in their evolution in each indi-
vidual. The smouldering CMM phenomenon was deﬁned
as metastases unexpectedly appearing and disappearing on
the same body region over months and years. In their wax
and wane progression the metastases usually reached at the
most the size of a pea or a bean [25]. Such condition was
likely associated with contrasted active cell proliferation and
apoptosis/necrosis.
The smouldering CMM phenomenon contrasts with the
more common surge appearance of metastatic crops. This
latter condition was particularly reported following excision
of some primary CMM at a time when the metastatic
disease remained silent and undisclosed. In short, smoul-
dering CMM highlights the fact that CMM progression
is not a ﬁxed process and an ineluctable feature. Indeed,
the net growth directionality of CMM metastasis proceeds
through a combination between growth and regression. This
evolution is inﬂuenced by (a) the possible prevalence of
apoptosis over proliferation, (b) the versatile antitumoral
immunity, and (c) the failure of stromal/vascular receptivity.
Of note, inﬂammation in a variety of neoplasms boosts
(a) the proliferation and survival of malignant cells, (b)
angiogenesis, (c) metastasis release, and (d) subversion of
adaptive immunity. In addition, inﬂammation potentially
alters the response of the neoplasm to hormones and various
chemotherapeutic agents [28]. Such a multifaceted process
possibly leads to a programmed pathway of apoptosis and
necrosis.
3. CMM Dormancy
Globally near 40% of CMM patients develop clinical metas-
tases 5 years or so after initial treatment. However, the
disease-freeintervalbeforeappearanceofmetastasespossibly
e l a p s e s1 0t o2 5y e a r so ro v e r .A n yu n u s u a l l yl o n gl a t e n c y
period between the primary CMM treatment and metastatic
occurrence is commonly thought to result from clinical
CMM dormancy [27]. It is associated with a protracted
progression-free survival. The relationship between the
CMM clinical dormancy and the CMM cell dormancy
is complex and probably multifactorial. The neoplastic
quiescence process is typically unstable and possibly leads to
CMM relapse [29]. Any delay in CMM metastases suggests
the implication of some host defence mechanism, and/or
a peculiar nature of non- or slow-proliferating CMM cells
possibly involving CMM stem cells [27].
Neoplastic dormancy and autophagy are partly corre-
lated. Autophagy is a homeostatic and catabolic process in-
volving cytoplasmic organelles and proteins. The process
enables particle sequestration and their lysosomal degrada-
tion. Overall, autophagy is a mechanism of stress tolerance
maintaining cell viability and possibly leading to any aspect
of tumoral dormancy, progression, and therapeutic resis-
tance [30]. Such a process is important for the maintenance
of genomic stability and cell survival.
A dramatic example of CMM dormancy deals with
metastases developed from transplant organs in drug-im-
munocompromised recipients [31, 32]. Silent micrometas-
tasespresentintheorgandonorsubjectdevelopinanuncon-
trolled brisky way when the invaded organ is transplanted in
the immunocompromised patient.
4.GrowthFractionandCellKineticsinCMM
Most cancers including CMM are composed of a number of
diﬀerent cell subpopulations expressing distinct cell kinetics,
as well as atypical ploidies, diﬀerent drug and radiation
sensitivities, and variable metastatic potential. Whatever the
source of cell heterogeneity, such cell diversity is present
at diﬀerent sites within each single neoplasm, at diﬀerent
metastatic locations in a given individual, and among pa-
tients exhibiting seemingly similar CMM types and stages.
The cell cycle of proliferation encompasses a sequential
series of biochemical events leading to DNA replication and
cell division [24]. The time elapsed between two successive
cell divisions in a sustained dividing process corresponds to
the cell cycle time (Tc). After mitosis completion, the cell
enters the G1-phase. At a speciﬁc restriction point in early
G1-phase, the cell sets in motion a speciﬁc biochemical step
allowing progression through an ordered sequence of other
biochemical steps leading to DNA replication during the S-
phase. Alternatively, the cell enters into the nondividing qui-
escent G0-stage, thereby reducing the growth fraction (GF)
of replicating cells. Once DNA duplication is completed, the
cellenterstheG2-phasethatendstheprocessrequiredforcell
division. At mitosis the cell divides into two daughter cells
which possibly reenter the G1-phase for reinitiating another
cell cycle.
GF of any tissue or any neoplasm corresponds to the
proportion of the cell population actually engaged in the cell
cycle of proliferation. Clearly, GF is reduced by any segment
of the cell population in the resting G0-stage. In addition,
cell loss from the dividing and nondividing compartments
occurs through cell apoptosis and necrosis as well as through
metastatic cell escape. Therefore, the rate of cancer growth
depends on three factors, namely, the average Tc, the GF, and
the cell loss.
The time to proceed through the S-, G2-a n dM - p h a s e s
of the cell cycle remains fairly constant in any given tissue.
By contrast, the extent in the G1-phase is more variable, in
part due to the diﬀerent restriction points controlling the
progress through the cell cycle or the derivation to the G0-
phase. The variability in the length of G1-phase makes Tc
frequently diﬀer from cell to cell. Neoplastic cells generally
exhibit a longer Tc than the corresponding normal cells. ThisISRN Dermatology 3
characteristic is in part explained by the presence of CMM
stem cells exhibiting a lengthy Tc [23]. The mechanisms
rulingthe proliferative activity(P)in agiventissuearelinked
to both GF and the speed rate of the cell cycle with P =
GF ∗ T−1
c . Thus, more of the GF and Tc singly deﬁnes the
actualP ofaneoplasm.Asarule,Tc isnotaccessibleclinically
and thus, P of CMM remains not measurable.
5. Immunohistochemistry andCMM
Growth Fraction
Both tumoral cell renewal and GF are important aspects
determining in part the CMM malignancy potential. Regular
counting of mitotic ﬁgures is a time-honored method used
for assessing cell proliferation, but its sensitivity and relia-
bility remain quite low because their numbers are usually
low.Toﬁne-tunesuchevaluation,anyimmunohistochemical
method exploring one single speciﬁc facet of cell renewal
requires the restricted expression or a prominent cell-
cycle-induced increase of a given target antigen in cycling
cells. A number of antibodies to cell-cycle-related proteins
fulﬁll such requirements. The target antigens belong to two
distinct categories. One group comprises speciﬁc molecular
compounds such as those involved in DNA synthesis during
the S-phase. The second group encompasses cell-cycle-
associated proteins, the most typical being represented by
some histones and the MIB/Ki-67 nuclear antigen.
The proliferation marker MIB1/Ki-67 is produced and
expressed during all active steps of the cell cycle of pro-
liferation (G1-, S-, G2-, and M-phases), but its production
is arrested in the G0-stage. The MIB1/Ki-67 monoclonal
antibody provides a convenient means for evaluating the GF
of CMM. The GF assessed by the Ki-67 index represents the
ratio of cycling cells to the overall cycling and noncycling
cells. Of note, cells that have run a part of the cell cycle
before being rerouted at a restriction point to the G0-
phase will retain the MIB/Ki-67 immunolabeling despite
the fact they are no more part of the GF [23, 24]. In
several malignancies, in particular CMM, the Ki-67 index is
indicative of the neoplastic progression, and it appears as an
important prognostic indicator [5, 7, 10–12, 23, 24, 33–39].
Globally, the ﬁndings about the GF of CMM support the
clinicalconceptdistinguishing CMMofhighandlowgrowth
rates, each bearing a diﬀerent prognosis [40–42]. Cancer
registries suggested the existence of three unrelated CMM
types recognized as (a) thick CMM, with stable incidence
over the past decades, (b) thin CMM mainly located on the
trunk, and showing a dramatic increase in incidence over the
past years, and (c) CMM mainly located on the head and
neck region showing a moderate trend in incidence increase
overtime[43,44].ThereisampleevidencethattheGFextent
in CMM is indicative of the neoplastic progression [13, 33–
37, 45–49]. Ki-67 immunolabeling is positive in less than
5% of nevocytes in most melanocytic nevi, but it commonly
raisesupto15%orsoinbenignatypicalmelanocytomasand
it reaches 15–30% or more in CMM [5, 7, 10–12, 33–37, 47].
Any MIB1/Ki-67 index in CMM does not predict the
number of cells completing mitosis. Indeed, all cycling cells
including those arrested at a restriction point in the G1-
phase are labeled. Hence, any fast-growing CMM is likely
associated with a high MIB/Ki-67 index but a high MIB/Ki-
67 index does not always imply a fast growing neoplasm.
A stochastic relationship apparently prevails between
CMM GF and tumor vascularity [38, 46]. Nevertheless,
clinically growth-stunted CMM appeared to be generally
associated with a restricted blood vascularization [47]. Thus,
it was inferred that the extent in blood microvasculature
and the GF size of CMM were mostly correlated when
angiogenesis was restricted [47]. Of note, the CMM GF
appears to be inﬂuenced by the intra- and peri-CMM
inﬁltration by Factor XIIIa-positive dendrocytes [34, 50, 51].
There is circumstantial evidence linking the density of Factor
XIIIa-positive dendrocytes and a low proliferative rate in
CMM cells [34]. The biologic and molecular mechanisms
supporting these ﬁndings remain unsettled.
Inshort,twomainclinicalapplicationsofthemelanocyte
kinetics emerge, namely, (a) deciphering the distinction
between benign melanocytic neoplasms and CMM and
(b) establishing or reﬁning a clinical prognosis for CMM
progression [8, 23, 24, 34–37].
6. CMM Phase Indexes
Two phase indexes are of particular interest in CMM. They
correspond to the S- and M-phases. Any phase index is
deﬁned as the proportion of cells engaged in that given phase
ofthecellcycle.Someofthesecellsarespeciﬁcallyrecognized
by morphology (mitosis), and others are possibly labeled (S-
phase). There is no ﬁxed correlation between the GF and
any speciﬁc phase index. Indeed, the proportion of cells in
a given cell cycle phase depends on both GF and the relative
duration of that cycle phase (phase duration/Tc). Diﬀerent
CMM cell populations, particularly their metastases, show
diﬀerent phase indexes due to (a) diﬀerences in their GF
while the ratios between their respective phase durations to
Tc aresimilar,(b)diﬀerencesintheratioofphasedurationto
Tc while their respective GF remains similar, (c) diﬀerences
in the total phase duration while their respective replicative
activity is similar, or (d) diﬀerences in their replicative
activities while their phase durations are similar [23, 24].
Among distinct CMM exhibiting diﬀerent phase indexes, the
neoplasm exhibiting the higher value in a given phase index
is not necessarily the most proliferative one.
A landmark study was performed 25 years ago using
incorporations of tritiated thymidine (3H-TdR) [52]. CMM
thickness appeared correlated with the proportion of CMM
cells in the S-phase of proliferation. The higher 3H-TdR
indexes were found in metastases.
The M-phase has long attracted attention in CMM. On
a descriptive ground, ﬁnding mitotic ﬁgures in the deep
portion of a melanocytic neoplasm was considered to be
suggestive for CMM. Quantitative assessments were used to
derive a prognostic factor (PF) following PF = M∗ tumor
thickness where M represented the number of mitosis per
mm2 [53]. More recently, a revival of mitosis interest
emerged in CMM [54–56] and in melanocytic nevi as well
[57]. Currently, it is possible to highlight mitoses using4 ISRN Dermatology
immunohistochemistry directed to speciﬁc M-associated
histones. Indeed, DNA is wrapped around histone octamers
to form the basic unit of chromatin structure. The octamer
is composed of histones H2A, H2B, H3, and H4, and it
associates with approximately 200 base pairs of DNA to
form the nucleosome. Histone H3, the core protein of the
nucleosome, becomes phosphorylated. The two major sites
of phosphorylation are the M-speciﬁc site Ser 10 and Ser 28,
bothofwhichareextensivelyphosphorylatedinDNA-bound
forms of histone H3 and in nucleosomal histone H3. The p-
histone H3 (Ser 10)-R detects Ser 10 phosphorylated histone
H3 [58, 59].
7.CMMStemCells
In the past decades, CMM evolution was commonly
described as the result of a “dediﬀerentiation” process of
transformed mature melanocytes, enabling a stepwise meta-
morphosis starting from the radial growth phase, evolving
toward the vertical growth phase, and ultimately leading to
the disseminated disease. More recently, the heterogeneity
and plasticity of the CMM cell populations led to the cancer
stem cell (CSC) concept [60–67]. The regular stem cells
of the melanocytic lineage are present in the human hair
follicle, the epidermis, and the dermis [18, 68, 69]. The
mutated melanocyte stem cells or immature melanocytic
progenitor cells present in the skin were considered as
p o s s i b l ep r e c u r s o r st oC M M[ 17, 18, 20, 64].
CSCs, also referred to as tumor-initiating cells, were
initially identiﬁed in several hematological malignancies and
severalsolidcancers[60,65].Similartophysiologicpostnatal
stem cells, CSCs are capable of self-renewal and diﬀerenti-
ation, and they are potentially involved in a perpetual self-
renewal, a function sustaining unlimited tumor growth [61].
Although conventional anticancer treatments eradicate most
of the target malignant cells, such drugs are typically inac-
tive against chemoresistant CSC. This failure is ultimately
responsible for neoplastic recurrence and progression. CMM
exhibits cell heterogeneity, various molecular signatures,
variable plasticity, and prominent tumorigenicity of some
CMM cell subsets. These features are probably related to the
involvement of CSC in the initiation and progression of the
neoplasm [17–23, 61–67].
Embryonic and postnatal physiologic stem cells are capa-
ble of self-renewal at a slow cycling rate ensuring perpetual
but discrete proliferation [61]. In addition, the multipotent
stem cells possibly diﬀerentiate into cell types of multiple
lineages, whereas unipotent stem cell give rise to a single
lineage [17–19, 60]. The stem-cell-derived cancer model
purports that most cancers are composed of relatively few
CSCs steadily undergoing self-renewal, thereby maintaining
a lifelong CSC pool. In addition, some other CSCs diﬀeren-
tiate into fast-growing transient ampliﬁer cells or progenitor
cells, that in turn diﬀerentiate into mature cancer cells with
limited proliferative potential [23, 70]. The latter cells form
the bulk of the neoplastic GF in the primary CMM and its
metastases.
Each CMM exhibits genetic and phenotypic hetero-
geneity, undiﬀerentiated molecular signatures, and various
developments of tumorigenicity and metastatic potential
[11, 17, 71]. Primary CMM initiating cells appear restricted
to CD133-positive (prominin-1) CSC, whereas CD133-
negative CMM cells apparently lack tumorigenicity [70].
The embryonic-like diﬀerentiation plasticity supports the
concept of involvement of CMM stem cells in the neoplastic
evolution, from tumor initiation to progression and metas-
tasis [71]. In addition, CMM contain some CSC-associated
proteins as well as progenitor cell-speciﬁc molecules includ-
ing cancer testis antigens [72] and bone morphogenetic
proteins [73]. Genetic aberrations in the signal-transduction
machinery of CSC survival and diﬀerentiation contribute
to both CMM progression and metastatic spreading. The
similarity of self-renewal mechanisms between physiologic
stem cells and CSC [74] is a further argument suggesting
the involvement of melanocytic stem cells in the CMM
pathogenesis.
Chemotherapy resistance of advanced CMM, particu-
larly in its metastatic stage, possibly results from several
mechanisms linked to CMM stem cell biology, including
the impairment of CMM apoptotic pathways, a relative
proliferation quiescence, and a restricted intracellular drug
accumulation. In particular, CMM cell dormancy [75]a n d
CMM recurrence following initial remission is possibly
related to the inability of current drug regimens to eradicate
the putative compartment of CMM stem cells [64, 76–78].
8. Cyclins in CMM
Threeoptionalphysiologicpathwaysconceptuallygovernthe
celllife.Accordingly,cellscontinuouslyproliferate,orsurvive
without further divisions, or die following apoptosis. The
decisionforacelltoproceedthroughtheproliferativecycleis
taken at two cardinal restriction checkpoints corresponding
tothecommitmenttoDNAreplicationandthecommitment
to mitosis at completion of the G2-phase. Throughout the
G1-phase, a number of growth factors inﬂuence the cell fate
through binding to speciﬁc surface receptors. This process
results in cell diﬀerentiation or proliferation following
activation of a signalling cascade regulating the transcription
of both immediate and delayed early response genes. Once
cells have entered the S-phase, they become refractory to a
series of growth-factor-induced stimuli. The next cell cycle
events are controlled by an intrinsic programme regulating
the progression through the G2-a n dM - p h a s e s .
Similarly to many other malignancies, CMM cells pro-
gress through deregulation of control mechanisms ruling
both cell proliferation and escape from programmed apop-
tosis [79]. Each cell cycle step is normally controlled by
the expression of a precise set of regulatory molecules.
Heteroprotein dimers combining a protein kinase and a
regulatory cyclin form the basic clockwork of the cell cycle
progression. A series of cyclins bind and activate cyclin-
dependent kinases. The diverse cyclins C, D1 (CCND1
gene product), D2, D3, and E as well as CDK2, p16INK4a,
p21CIP1, and p27KIP1 drive the cell cycle of proliferation in its
progressionduringtheG1-totheS-phase.CyclinAnormally
regulates the passage from the S- to G2-phase, and cyclin B
from the G2-phase to mitosis [80].ISRN Dermatology 5
Melanocytic nevi rarely express cyclin A, B, D1, and D3.
By contrast, these cyclins are commonly present in CMM
[80]. In some CMM, a negative correlation was pointed out
between cyclin A expression and the disease-free survival
[81]. The cyclin B and D1 prognostic relevance remains
unsettled in CMM. Of note, the GG-CCND1 mutation
(A8706-CCND1 polymorphism) in peripheral blood cells
represents a genetic predisposition for CMM. Increased
cyclinD3wasreportedtobeassociatedwithearlyrelapseand
decreased survival in thin CMM, but not in thicker CMM
[82]. Cyclin E expression appeared to be negatively related
with survival of CMM patients [10, 83].
Cyclin-dependent kinase inhibitors downregulate pro-
gression through the cell cycle of proliferation [10, 80]. For
instance,p16normallyinactivatescyclinD/CDK4complexes
in most melanocytic nevi [84–86]. By contrast, p16 expres-
sion is lost in most of the invasive, recurrent, and metastatic
CMM [84–87]. This feature appears to be associated with
decreased survival, although it does not seem to represent an
independent prognostic parameter [80].
The p21 protein is rarely present in melanocytic nevi.
By contrast, it shows increased immunoreactivity in CMM
[88]. It inhibits cyclin/CDK complexes, binds to PCNA
and thus, it inhibits DNA polymerase δo. Any relationship
between increased p21 immunoreactivity and CMM out-
come remains unsettled.
The p27 protein inhibits both cyclin D/CDK4 and cyclin
E/CDK2 complexes. Thus, it blocks the cell cycle progression
from the G1- to S-phase [89, 90]. A clear p27 expression
distinction is not established between melanocytic nevi and
CMM. Thick CMM with a p27 index lower than 5% might
beatincreasedriskforearlyrelapse.However,themagnitude
in p27 expression has no eﬀect on the overall survival
[88].
The p53 gene is commonly mutated in cancers. The
normal wild-type p53 protein is a 53-kDa tumor suppressor
protein blocking the cell cycle at both the G1-a n dG 2-
phases,allowingrepairoftheDNAdamage[91].Inaddition,
p53 induces the expression of p21 contributing to inhibit
DNA synthesis [88]. Mutations of the p53 gene produce
abnormal p53 proteins unable to inhibit the cell cycle. As
the regular p53 protein is short lived, it is not detected using
immunohistochemistry. By contrast, the long-lived mutated
p53 protein is conveniently disclosed using immunohis-
tochemistry. Accordingly, p53 protein is not revealed in
most melanocytic nevi, but is present in its mutated form
in 25–60% of CMM [14, 88, 91–93]. Overexpression of
the p53 protein was reported in CMM originating from
a precursor p53-negative melanocytic nevus [92]. Some
benign melanocytomas show nearly 10% cell positivity for
the mutated p53 protein [94]. A correlation was disclosed
between p53 expression and thicker CMM [95]. However,
no correlation was found between p53 immunoreactivity
and likelihood of metastasis, recurrence, and global CMM
survival.
HDM2 is a 90-kDa zinc ﬁnger protein that binds to
the transcription activation domain of the p53 gene [96,
97]. Increased HDM2 immunostaining might represent an
independent prognostic factor paradoxically associated with
decreased recurrence rates and increased survival in CMM
[97].
9.Mitogen-Activated ProteinKinase Pathway
inCMM
Gene expression proﬁles characterize cells from any given
tissue. Alterations of these patterns potentially disrupt cell
homeostasis leading to some diseases including cancer.
Compared to regular melanocytes, a number of primary
and secondary mutations were reported in advanced CMM.
A primary clonal event in neoplastic progression possibly
contributes to the malignancy. This process is possibly based
on a genetic origin (gene mutation, deletion, ampliﬁcation,
or translocation). Such defect occurs independently, rather
than as a secondary event following some other oncogenic
changes. Alternatively, epigenetic alterations possibly result
from heritable changes generally corresponding to tran-
scriptional modulation following DNA methylation, and/or
by chromatin alterations resulting from histone alteration.
Clonal evolution of cancer initiates new clones exhibiting
growth advantage over other cells, or an alternative selective
advantage such as migration potential [98].
T h eg e n ep r o d u c t ss u b j e c tt op r i m a r yc l o n a la l t e r a t i o n s
in CMM correspond to activated or ampliﬁed genes, and
conversely to other inactivated or deleted genes. Hundreds
of secondary changes were described in CMM [99–103].
However, there are limitations to the interpretations of
reported data. Indeed, genes were often tested only for muta-
tions, rather than for deletions or ampliﬁcations. Hence,
frequencies of aberration are probably underestimated [16].
In addition, some studies focused on cell lines, while others
used uncultured native tissues. Both procedures commonly
provided diﬀerent results.
A number of signalling pathways are critical to the sur-
vival and growth of CMM cells. The most important path-
way is the mitogen-activated protein kinase (MAPK) cas-
cade. It includes the MAPK kinase (MEK) which is just
downstream BRAF, the extracellular signal-regulated protein
kinase (ERK), and the p38 MAPK and the Jun NH2-terminal
protein kinase (JNK) activation pathways [104]. MAPK acti-
vation is linked to the induction of the transcription factor
AP-1 regulating the expression of a series of genes involved
in the regulation of both cell growth and diﬀerentiation. The
MAPK pathway is activated and altered in nearly all CMM.
It is involved in the neoplastic proliferation, invasion, and
survival [105, 106] through the RAS/RAF/MEK/ERK signal
transduction pathway regulating cell growth.
MAPK signalling is initiated at the cell membrane, either
by tyrosine kinases (RTKs) binding ligand or by integrin
adhesion to the extracellular matrix. This latter event acti-
vates the RAS-GTPase at the cell membrane inner surface
[107, 108]. GTP-bound RAS binds eﬀector proteins, boost-
ing cell proliferation, diﬀerentiation, and survival through
activation of various signalling pathways [108]. RAF and
phosphatidylinositol 3-kinase (PI3K) are well-characterized
RAS eﬀector proteins.
The RAF protein family is composed of serine/threonine
kinases. It includes three proteins, ARAF, BRAF, and CRAF6 ISRN Dermatology
(corresponding to RAF-1) coded by unique genes [109–
111]. Any RAF family member activates the MAPK pathway,
although each isoform possesses a distinct expression proﬁle
with unique phosphorylation targets and signalling eﬀects
[110]. RAF is the primary link between RAS and the MAPK
pathway. RAF has long been identiﬁed as a protooncogene
[112]. It activates the cascade of proliferative or survival
signals through phosphorylation of a number of cytoplasmic
targets [14, 113].
Over 50 BRAF mutations have been identiﬁed inside the
kinase domain. The most common is the replacement of
glutamic acid by valine in the position 600, the so-called
V600E BRAF mutation [114–117]. This single aminoacid
substitution accounts for 80–90% of the BRAF gene muta-
tions [109, 112, 118–121]. In addition, RAS is mutated in
approximately 15% of cancers including CMM [109]. The
V600E mutant expresses a 10-fold increased kinase activity
compared to the wild-type BRAF [109].
BRAF is mutated in about 7–30% of human cancers, but
this mutation is present in almost 60–80% of CMM [107–
111,113,119,122].BRAFmutationswerefoundinanumber
of melanocytic nevi as well [109, 120, 121]. The presence of
BRAF mutations in melanocytic nevi suggests that a single
BRAF mutation in the MAPK pathway as found in CMM is
probably inadequate to promote malignant transformation
[109, 119, 120, 123, 124]. Rather a single BRAF mutation
appears to represent a senescence factor in melanocytes and
melanocytic nevi [124]. Another oncogenic hit is therefore
necessary including the interaction of BRAF with PTEN
[125], p16 [124], p53 [123], AKT [126], and UV radiation
[127]. The NRAS and BRAF mutations present in CMM
exhibit some characteristic UV radiation-induced changes.
The target of UV injury leading to such mutations remains
unclear [113, 128].
Clearly, histopathologic assessments point to the fact
that the majority of CMM occur outside a precursor mel-
anocytic lesion [128]. In general, CMM originating from a
melanocyticnevusexhibitbothaBRAFmutationorareboth
negative for the mutation [129, 130].
In primary CMM, the genomewide alterations in DNA
copy number, as well as BRAF and NRAS mutations [131],
suggest the role of BRAF kinase both in CMM development
and CMM heterogeneity [14]. Increased BRAF mutations
are found in both nodular and superﬁcial spreading CMM,
contrasting with acral lentiginous CMM, lentigo maligna,
and mucosal CMM [132–134]. CMM with the highest prev-
alence of BRAF mutations were those associated with
intermittent sun exposure [132]. This relationship reveals
a stringent relationship between sporadic UV exposure,
BRAF/NRAS mutations, and additional genetic events in
CMM [80, 122]. CMM without either mutation often
exhibit increased copies of CDK4 or CCND1. Furthermore,
no CMM with CDK4 ampliﬁcation exhibited concomitant
NRAS or BRAF mutations, or CCND1 ampliﬁcation. Such
ﬁndingsuggestsoverlappingfunctionsoftheMAPKpathway
and the CCND1/CDK4 pathways with independent onco-
genic functions. The overall incidence of BRAF and NRAS
mutations was signiﬁcantly lower in CMM developed on
chronic sun-damaged (CSD) skin as well as on sun-shielded
sites, with BRAF and NRAS mutations being mutually exclu-
sive. The CMM thickness had apparently no inﬂuence on
frequency of mutation in BRAF or NRAS, or ampliﬁcation
(CCND1 or CDK4). In CMM developed on CSD, BRAF
mutations were rare and CCND1 copy gain predominated
[135]. Conversely, in CMM developed outside CSD, mutant
BRAF and chromosome 10 (site of PTEN) loss were both
common.
An important link between germline mutations of the
melanocortin-1 receptor (MC1R) and BRAF mutations is
possible [136]. Although MC1R variants were identiﬁed as
risk factors for CMM [137], the precise link to sun exposure
and genetic events in primary CMM remains unclear. MC1R
variant alleles were found to be associated with CMM
risk, speciﬁcally in CMM developed outside CSD. Such risk
was associated with neoplasms harbouring BRAF mutations
suggesting that germline events largely inﬂuenced genetic
eventsleadingtotumorigenesisinresponsetoenvironmental
UV exposures.
The enhancement of mitogenic activity in skin cancers
is possibly reﬂected by the diﬀerence of intrinsic mitogenic
signallingpathways[138].Asignallingpathwayinvolvesacti-
vation of the MAPK family, whose molecular components
play a complex role in the determination of cell growth.
It appears that p38 MAPK is activated by UV irradiation,
cytokines, hormones, and some stresses such as osmotic
shockandheatshock.Itsprognosticvalueispossibleinsome
malignancies [139].
10.Apoptosis inCMM
Programmed cell death or apoptosis is diﬀerent in its self-
destruction from necrotic cell death. It represents one major
mechanism involved in reducing the expansile growth of
melanocyticneoplasms.Asafunctionalcounterpartofmito-
sis, apoptosis plays a crucial role and is normally ﬁrmly regu-
lated. Apoptosis is altered in melanocytic neoplasms when
the components and regulators of the cellular apoptotic
machinery are mutated or present in inappropriate amounts.
In CMM, the molecular apoptosis machinery includes posi-
tive (proapoptotic) and negative (antiapoptotic) regulators
[140–143]. The former includes p53, Bid, Noxa, PUMA,
Bax, TNFα, TRAIL, Fas/FasL, PITSLRE, interferons (IFN),
and c-KIT/SCF. The antiapoptotic regulators include Bcl-2,
Bcl-XL, Mcl-1, NF-KB, survivin, livin, AKT, and ML-LAP
[91, 94, 144]. Alternatively, some molecules such as TRAF-
2, c-Myc, endothelin, and integrins either exhibit pro- or
antiapoptotic eﬀects. In addition, the PI3K pathway is acti-
vated following the biding of a ligand to a receptor tyrosine
kinase (RTK). It interacts with multiple cellular mechanisms
ofapoptosis,survival,proliferation,mobility,diﬀerentiation,
and growth. The phosphatase and tensin homolog (PTEN) is
a tumor suppressor gene. Its protein product inhibits CMM
growth and increases its susceptibility to apoptosis [145].
The deletion or silencing of PTEN increases the level of
AKT3phosphorylationinmelanocytesandearly-stageCMM
cells.
A small CMM subset (2 to 5%) presents ampliﬁcation or
mutation in c-Kit. It is more frequent in sun-shielded areas,ISRN Dermatology 7
such as in the mucous and acral CMM types, although it can
be found on CSD areas [146, 147].
Bcl-2isaprotooncogenethatisnotinvolvedinthemech-
anisms of cell proliferation, but instead inﬂuences tissue
homeostasis regulated by apoptosis. The gene encodes for a
protein that preserves cells from apoptosis, allowing them
to survive in G0-phase even in the absence of essential
growth factors. The Bcl-2 protein is conveniently detected
using immunohistochemistry. It is expressed in most CMM
and melanocytic nevi [148] suggesting that its expression
is a common ﬁnding in cutaneous melanocytic tumors
regardless of their biologic behavior. Expression of the Bcl-2
proteininthevastmajorityofCMMrulesoutanyprognostic
signiﬁcance of Bcl-2 in CMM.
Some of the apoptosis-related molecules are of potential
therapeutic use, including (a) p53, which inﬂuences resis-
tancetochemotherapy,(b)Mcl-1andBcl-XL,whichoverride
apoptosis,(c)TRAIL,whichhasselectivefataleﬀectsonneo-
plastic cells, (d) downregulated NF-KB, which sensitizes cells
to TRAIL and TNF, (e) PITSLRE kinases, whose alteration
appears to result in Fas resistance, (f) IFN sensitizing cells to
other factors, and (g) survivin that inhibits apoptosis.
Impaired regulation of apoptosis is associated with the
development of various cancers. Fas binding to its ligand,
Fas ligand (Fas-L), is expressed by CMM cells and plays a
role in tumoral escape from immune surveillance [141, 149].
Apoptotic activity appeared minimal in CMM and moderate
in Spitz melanocytomas. By contrast, melanocytic nevi
demonstrated more intense apoptosis in the deep portion
of the tumor. Fas was found to be expressed by all Spitz
melanocytomas, most melanocytic nevi, and approximately
half of the CMM. Fas expression was signiﬁcantly more
pronounced in Spitz melanocytomas as compared with the
two other neoplasms. Fas-L was shown to be more expressed
a n dm o r ef r e q u e n ti nC M Mc e l l sa sc o m p a r e dt on e v u sc e l l s .
11. Conclusion
When CMM frequency emerged a few decades ago, der-
matologists, dermatopathologists, and oncologists clearly
underestimated the impact and relevance of CMM cell
proliferation including CMM stem cells. These limitations
were obstacles to tackling CMM beyond the stage of the
primary neoplasm often curable by surgery alone. With the
improvement of dermatopathology and molecular biology
beyond routine histopathology, skilled researchers were able
to better assess the neoplastic CMM progression. They
tackled many facets of CMM with both increased knowledge
and the beneﬁt of hindsight. There is evidence that future
CMM treatments will target some speciﬁc molecular steps
of the neoplastic cell cycle of proliferation and the apoptosis
pathways.
The links between the clinical evolution, cell prolifera-
tion/apoptosis, and key molecular aberrations are progres-
sively elucidated in CMM. These advances represent key fac-
tors supporting the identiﬁcation and distinction of diﬀerent
CMMtypes,includingthegrowth-stunted,theslow-growing
accretive growth and the fast-growing expansile proliferative
neoplasms.
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